AMENDMENTS TO THE CLAIMS

In the Claims:

Claims 35-51 have been canceled without prejudice or disclaimer.

Please amend claims 1, 6-17, 20, 23-34 and 53-55 as shown below.

1. (Currently amended) A combination product for ~~use in~~ the treatment of cancer in a mammal, said combination product comprising: an antisense oligonucleotide of between 7 and 100 nucleotides in length comprising at least 7 consecutive nucleotides complementary to a mammalian ribonucleotide reductase R2 subunit mRNA and one or more immunotherapeutic agents.

2. (Original) The combination product according to claim 1, wherein said mammalian ribonucleotide reductase R2 subunit mRNA is a human ribonucleotide reductase R2 subunit mRNA.

3. (Original) The combination product according to claim 2, wherein said human ribonucleotide reductase R2 subunit mRNA has a sequence as set forth in SEQ ID NO:105.

4. (Original) The combination product according to claim 2, wherein said antisense oligonucleotide comprises at least 7 consecutive nucleotides of the sequence as set forth in any one of SEQ ID NOs:1 and 4-104.

5. (Original) The combination product according to according to claim 2, wherein said antisense oligonucleotide comprises at least 7 consecutive nucleotides of the sequence as set forth in SEQ ID NO:1.

6. (Currently amended) The combination product according to ~~any one of claims 1 to 5~~claim 1, wherein said antisense oligonucleotide comprises one or more phosphorothioate internucleotide linkages.

7. (Currently amended) The combination product according to ~~any one of claims 1 to 6~~claim 1, wherein said cancer is an advanced cancer.

8. (Currently amended) The combination product according to ~~any one of claims 1 to 7~~claim 1, wherein said cancer is a metastatic cancer.

9. (Currently amended) The combination product according to ~~any one of claims 1 to 8~~claim 1, wherein said treatment is a first-line systemic therapy.

10. (Currently amended) The combination product according to ~~any one of claims 1 to 9~~claim 1, wherein said one or more immunotherapeutic agents are non-specific immunotherapeutic agents.

11. (Currently amended) The combination product according to ~~any one of claims 1 to 9~~claim 1, wherein said one or more immunotherapeutic agents are specific immunotherapeutic agents.

12. (Currently amended) The combination product according to ~~any one of claims 1 to 10~~claim 1, wherein said one or more immunotherapeutic agents are ~~selected from the group of:~~ a cytokine, a non-cytokine adjuvant, a monoclonal antibody ~~and~~or a cancer vaccine.

13. (Currently amended) The combination product according to ~~any one of~~

~~claims 1 to 10~~claim 1, wherein said one or more immunotherapeutic agents are ~~selected from the group of:~~ a cytokine ~~and~~or a non-cytokine adjuvant.

14. (Currently amended) The combination product according to ~~any one of claims 1 to 10~~claim 1, wherein said one or more immunotherapeutic agents are one or more cytokines.

15. (Currently amended) The combination product according to ~~any one of claims 1 to 14~~claim 1, wherein said combination product further comprises one or more chemotherapeutic agents.

16. (Currently amended) The combination product according to ~~any one of claims 1 to 15~~claim 1, wherein said cancer is a solid cancer.

17. (Currently amended) The combination product according to ~~any one of claims 1 to 16~~claim 1, wherein said mammal is a human.

18. (Original) A method of treating cancer in a mammal comprising administering to said mammal a combination product comprising:

(a) an antisense oligonucleotide of between 7 and 100 nucleotides in length comprising at least 7 consecutive nucleotides complementary to a mammalian ribonucleotide reductase R2 subunit mRNA, and

(b) one or more immunotherapeutic agents.

19. (Original) The method according to claim 18, wherein said mammalian ribonucleotide reductase R2 subunit mRNA is a human ribonucleotide reductase R2 subunit mRNA.

20. (Currently amended) The ~~combination product~~method according to claim 19, wherein said human ribonucleotide reductase R2 subunit mRNA has a sequence as set forth in SEQ ID NO:105.

21. (Original) The method according to claim 19, wherein said antisense oligonucleotide comprises at least 7 consecutive nucleotides of the sequence as set forth in any one of SEQ ID NOs:1 and 4-104.

22. (Original) The method according to according to claim 19, wherein said antisense oligonucleotide comprises at least 7 consecutive nucleotides of the sequence as set forth in SEQ ID NO:1.

23. (Currently amended) The method according to ~~any one of claims 18 to 22~~claim 18, wherein said antisense oligonucleotide comprises one or more phosphorothioate internucleotide linkages.

24. (Currently amended) The method according to ~~any one of claims 18 to 23~~claim 18, wherein said cancer is an advanced cancer.

25. (Currently amended) The method according to ~~any one of claims 18 to 24~~claim 18, wherein said cancer is a metastatic cancer.

26. (Currently amended) The method according to ~~any one of claims 18 to 25~~claim 18, wherein said combination product is administered to said mammal as first-line systemic therapy.

27. (Currently amended) The method according to ~~any one of claims 18 to 26~~claim 18, wherein said one or more immunotherapeutic agents are non-specific immunotherapeutic agents.

28. (Currently amended) The method according to ~~any one of claims 18 to 26~~claim 18, wherein said one or more immunotherapeutic agents are specific immunotherapeutic agents.

29. (Currently amended) The method according to ~~any one of claims 18 to 27~~claim 18, wherein said one or more immunotherapeutic agents are ~~selected from the group of:~~ a cytokine, a non-cytokine adjuvant, a monoclonal antibody ~~and~~or a cancer vaccine.

30. (Currently amended) The method according to ~~any one of claims 18 to 27~~claim 18, wherein said one or more immunotherapeutic agents are ~~selected from the group of:~~ a cytokine ~~and~~or a non-cytokine adjuvant.

31. (Currently amended) The method according to ~~any one of claims 18 to 27~~claim 18, wherein said one or more immunotherapeutic agents are one or more cytokines.

32. (Currently amended) The method according to ~~any one of claims 18 to 31~~claim 18, wherein said combination product further comprises one or more chemotherapeutic agents.

33. (Currently amended) The method according to ~~any one of claims 18 to 32~~claim 18, wherein said cancer is a solid cancer.

34. (Currently amended) The method according to ~~any one of claims 18 to 33~~claim 18, wherein said mammal is a human.

35. – 51. (Canceled)

52. (Original) A pharmaceutical kit comprising a combination product for the treatment of cancer, said combination product comprising:

(a) an antisense oligonucleotide of between 7 and 100 nucleotides in length comprising at least 7 consecutive nucleotides complementary to a mammalian ribonucleotide reductase R2 subunit mRNA, and

(b) one or more immunotherapeutic agents.

53. (Currently amended) A combination product for ~~use in~~ the treatment of renal cancer in a subject, said combination product comprising: an antisense oligonucleotide of between 7 and 100 nucleotides in length comprising at least 7 consecutive nucleotides complementary to SEQ ID NO:1 and one or more cytokines.

54. (Currently amended) The combination product according to claim 53, wherein said one or more cytokines are ~~selected from:~~ interferon alpha ~~and~~or interleukin-2.

55. (Currently amended) The combination product according to claim 53 ~~or 54~~, wherein said treatment is a first-line systemic therapy.